BioLineRx Management

Management criteria checks 2/4

BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 7.75 years. total yearly compensation is $952.00K, comprised of 29.4% salary and 70.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth €6.50K. The average tenure of the management team and the board of directors is 7.4 years and 2.6 years respectively.

Key information

Phil Serlin

Chief executive officer

US$952.0k

Total compensation

CEO salary percentage	29.4%
CEO tenure	7.8yrs
CEO ownership	0.01%
Management average tenure	7.4yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Phil Serlin's remuneration changed compared to BioLineRx's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$952k	US$280k	-US$61m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$1m	US$297k	-US$25m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$903k	US$290k	-US$27m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$34m
Dec 31 2020	US$958k	US$250k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$678k	US$256k	-US$25m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$846k	US$254k	-US$23m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$26m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$612k	US$240k	-US$24m

Compensation vs Market: Phil's total compensation ($USD952.00K) is above average for companies of similar size in the German market ($USD533.87K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Serlin (64 yo)

7.8yrs

Tenure

US$952,000

Compensation

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philip Serlin	Chief Executive Officer	7.8yrs	US$952.00k	0.014% $ 6.4k
Mali Zeevi	Chief Financial Officer	7.8yrs	US$443.00k	0.027% $ 12.2k
Ella Sorani	Chief Development Officer	7.4yrs	US$520.00k	0.0055% $ 2.5k
Holly May	President of BioLineRx USA	2.1yrs	US$1.01m	no data
John Lacey	Head of Corporate Communications & Investor Relations	no data	no data	no data
Tsipi Keren-Lehrer	Head of BD & Strategic Advisor	4.9yrs	no data	no data
Raziel Fried	Treasurer & Budgetary Control Director	no data	no data	no data

7.4yrs

Average Tenure

59yo

Average Age

Experienced Management: YP2A's management team is seasoned and experienced (7.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Aharon Schwartz	Chairman of the Board	20.5yrs	no data	0.31% $ 137.3k
Sandra Panem	Director	10.4yrs	no data	no data
Avraham Molcho	Independent External Director	14yrs	US$26.55k	no data
Raphael Hofstein	Director	21.5yrs	US$140.92k	no data
Ronald Levy	Member of Immuno-Oncology Scientific Advisory Board	2.6yrs	no data	no data
Rami Dar	Independent External Director	2yrs	no data	no data
Gal Cohen	Independent Director	less than a year	no data	no data
Barbar-Jean Bormann-Kennedy	Director	10.9yrs	no data	no data
Jon Marc Wigginton	Member of Immuno-Oncology Scientific Advisory Board	2.6yrs	no data	no data
Ignacio Melero	Member of Immuno-Oncology Scientific Advisory Board	2.6yrs	no data	no data
Aurelien Marabelle	Member of Immuno-Oncology Scientific Advisory Board	2.6yrs	no data	no data
Shaoyu Yan	Director	less than a year	no data	no data

2.6yrs

Average Tenure

66yo

Average Age

Experienced Board: YP2A's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

BioLineRx Management

Management criteria checks 2/4

Key information

Recent management updates

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

Recent updates

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

BioLineRx Ltd. announced that it has received $14.6 million in funding

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age